Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) 고위험도 성인 환자의 기증자 특이 항체로 인한 원발성 기증 조직 부작용에 대한 표준 감마화 전 알로지네이크 뼈마리우스 또는 주위혈 세포 조가체 이식 전

간략 요약

This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patients to proceed with allogeneic peripheral blood transplant (alloBMT). Those being asked to participate have high DSA levels that puts those being asked to participate at high risk of rejecting the available donor's blood stem cells and making those being asked to participate ineligible to receive a stem cell transplant.